EYPT Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -357.26% compared to EyePoint Pharmaceuticals's net margin of -49.65%. EyePoint Pharmaceuticals's return on equity of -50.34% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

EyePoint Pharmaceuticals has a consensus price target of $33.00, signalling upside risk potential of 397.74%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 31.89%. Given that EyePoint Pharmaceuticals has higher upside potential than NovaBay Pharmaceuticals, analysts believe EyePoint Pharmaceuticals is more attractive than NovaBay Pharmaceuticals.

EyePoint Pharmaceuticals has a beta of 1.409, which suggesting that the stock is 40.932% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.726, suggesting its less volatile than the S&P 500 by 27.362%.

EyePoint Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EyePoint Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

EyePoint Pharmaceuticals quarterly revenues are $11.6M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. EyePoint Pharmaceuticals's net income of -$41.4M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, EyePoint Pharmaceuticals's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EyePoint Pharmaceuticals is 8.63x versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Ocugen has a net margin of -357.26% compared to EyePoint Pharmaceuticals's net margin of -1816.75%. EyePoint Pharmaceuticals's return on equity of -50.34% beat Ocugen's return on equity of -171.04%.

EyePoint Pharmaceuticals has a consensus price target of $33.00, signalling upside risk potential of 397.74%. On the other hand Ocugen has an analysts' consensus of $6.75 which suggests that it could grow by 1078.83%. Given that Ocugen has higher upside potential than EyePoint Pharmaceuticals, analysts believe Ocugen is more attractive than EyePoint Pharmaceuticals.

EyePoint Pharmaceuticals has a beta of 1.409, which suggesting that the stock is 40.932% more volatile than S&P 500. In comparison Ocugen has a beta of 3.883, suggesting its more volatile than the S&P 500 by 288.285%.

EyePoint Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocugen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EyePoint Pharmaceuticals pays -- of its earnings as a dividend. Ocugen pays out -- of its earnings as a dividend.

EyePoint Pharmaceuticals quarterly revenues are $11.6M, which are larger than Ocugen quarterly revenues of $764K. EyePoint Pharmaceuticals's net income of -$41.4M is lower than Ocugen's net income of -$13.9M. Notably, EyePoint Pharmaceuticals's price-to-earnings ratio is -- while Ocugen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EyePoint Pharmaceuticals is 8.63x versus 38.26x for Ocugen. Usually stocks with elevated PS ratios are considered overvalued.

Ocular Therapeutix has a net margin of -357.26% compared to EyePoint Pharmaceuticals's net margin of -283.27%. EyePoint Pharmaceuticals's return on equity of -50.34% beat Ocular Therapeutix's return on equity of -62.66%.

EyePoint Pharmaceuticals has a consensus price target of $33.00, signalling upside risk potential of 397.74%. On the other hand Ocular Therapeutix has an analysts' consensus of $17.50 which suggests that it could grow by 120.4%. Given that EyePoint Pharmaceuticals has higher upside potential than Ocular Therapeutix, analysts believe EyePoint Pharmaceuticals is more attractive than Ocular Therapeutix.

EyePoint Pharmaceuticals has a beta of 1.409, which suggesting that the stock is 40.932% more volatile than S&P 500. In comparison Ocular Therapeutix has a beta of 1.337, suggesting its more volatile than the S&P 500 by 33.685%.

EyePoint Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocular Therapeutix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EyePoint Pharmaceuticals pays -- of its earnings as a dividend. Ocular Therapeutix pays out -- of its earnings as a dividend.

EyePoint Pharmaceuticals quarterly revenues are $11.6M, which are smaller than Ocular Therapeutix quarterly revenues of $17.1M. EyePoint Pharmaceuticals's net income of -$41.4M is higher than Ocular Therapeutix's net income of -$48.4M. Notably, EyePoint Pharmaceuticals's price-to-earnings ratio is -- while Ocular Therapeutix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EyePoint Pharmaceuticals is 8.63x versus 19.72x for Ocular Therapeutix. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -357.26% compared to EyePoint Pharmaceuticals's net margin of 24.22%. EyePoint Pharmaceuticals's return on equity of -50.34% beat Regeneron Pharmaceuticals's return on equity of 15.78%.

EyePoint Pharmaceuticals has a consensus price target of $33.00, signalling upside risk potential of 397.74%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $923.05 which suggests that it could grow by 36.06%. Given that EyePoint Pharmaceuticals has higher upside potential than Regeneron Pharmaceuticals, analysts believe EyePoint Pharmaceuticals is more attractive than Regeneron Pharmaceuticals.

EyePoint Pharmaceuticals has a beta of 1.409, which suggesting that the stock is 40.932% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.270, suggesting its less volatile than the S&P 500 by 72.991%.

EyePoint Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0.13% to investors and pays a quarterly dividend of $0.88 per share. EyePoint Pharmaceuticals pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

EyePoint Pharmaceuticals quarterly revenues are $11.6M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3.8B. EyePoint Pharmaceuticals's net income of -$41.4M is lower than Regeneron Pharmaceuticals's net income of $917.7M. Notably, EyePoint Pharmaceuticals's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 17.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EyePoint Pharmaceuticals is 8.63x versus 5.50x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.